FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966924789> ?p ?o ?g. }

• W1966924789 abstract "Background: Most patients with metastatic breast cancer are treated with chemotherapies and/or targeted therapies. These therapies have toxicity profiles that vary with agent(s) used. Patient attitudes towards different adverse events (AE9s) may vary and factor into treatment decisions. Different patients may have specific feelings about tolerable and unacceptable AE9s, especially when balanced against possible treatment benefit. As more agents/combinations become available, it becomes increasingly important to understand which adverse events impact treatment decisions. Previous research has shown that conjoint analysis (CA) is a valid methodology that allows patients to express preferences and is particularly useful when designed based on specific treatment profiles (Smith, ASCO 2011; Smith, ASCO 2012). Methods: The objective of this study was to assess patient preferences using CA based on profiles of two MBC regimens (trastuzumab+docetaxel and T-DM1). Patients were presented pairs of hypothetical treatments (describing benefit, AE9s, and cost) and asked what their preferred alternative was; a follow-up question asked if they would take the treatment if it were the only option available. Five AE9s (alopecia, peripheral neuropathy, diarrhea, fatigue, and neutropenia) with differing likelihood, severity, and/or duration were included. There were 3 stages in preparing the CA survey: the first comprised two online focus groups conducted with patients with metastatic disease. Stage 2 included the development of the CA survey using patient language to describe the AE9s and their impact, as well as images to represent likelihoods, progression-free survival (PFS), and costs. Stage 3 is initiating and will recruit patients with the assistance of several breast cancer organizations (target n= 600). Analysis of response patterns allows study of the influence of each variable and provides a basis for prediction of treatment choice for any combination of benefit, AE9s, and cost. Final analysis will be complete in September 2012. Results: Findings from the focus groups facilitated an understanding of PFS, of experience with and impact of the AE9s on decision-making, and of attitudes. In Stage 2, the survey was pretested with seven patients and took approximately 20 minutes to complete. Feedback suggested the questions were relevant and realistic. Suggestions allowed for improvement of the CA explanatory material, as well as refinement of a few answer choices to questions outside the CA section of the survey. Final study results will present the proportion of patients who are predicted to prefer each of two treatment profiles, the impact of each attribute level on treatment preference and differing preferences seen in patient subgroups. This information will provide valuable insight into patient preferences and inform future development of new therapies. In addition, these results may generate discussion and consideration of patient preferences in conversations about patient care and treatment selection. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-09-11." @default.
• W1966924789 created "2016-06-24" @default.
• W1966924789 creator A5037998826 @default.
• W1966924789 creator A5072015843 @default.
• W1966924789 creator A5084458085 @default.
• W1966924789 creator A5091126685 @default.
• W1966924789 date "2012-12-15" @default.
• W1966924789 modified "2023-09-26" @default.
• W1966924789 title "Abstract P6-09-11: Examining patient treatment choices involving efficacy, toxicity, and cost tradeoffs in the metastatic breast cancer setting" @default.
• W1966924789 doi "https://doi.org/10.1158/0008-5472.sabcs12-p6-09-11" @default.
• W1966924789 hasPublicationYear "2012" @default.
• W1966924789 type Work @default.
• W1966924789 sameAs 1966924789 @default.
• W1966924789 citedByCount "0" @default.
• W1966924789 crossrefType "proceedings-article" @default.
• W1966924789 hasAuthorship W1966924789A5037998826 @default.
• W1966924789 hasAuthorship W1966924789A5072015843 @default.
• W1966924789 hasAuthorship W1966924789A5084458085 @default.
• W1966924789 hasAuthorship W1966924789A5091126685 @default.
• W1966924789 hasConcept C121608353 @default.
• W1966924789 hasConcept C126322002 @default.
• W1966924789 hasConcept C143998085 @default.
• W1966924789 hasConcept C146357865 @default.
• W1966924789 hasConcept C151730666 @default.
• W1966924789 hasConcept C177713679 @default.
• W1966924789 hasConcept C197934379 @default.
• W1966924789 hasConcept C2775930923 @default.
• W1966924789 hasConcept C2777063308 @default.
• W1966924789 hasConcept C2777909004 @default.
• W1966924789 hasConcept C2779134260 @default.
• W1966924789 hasConcept C2781190966 @default.
• W1966924789 hasConcept C29730261 @default.
• W1966924789 hasConcept C526805850 @default.
• W1966924789 hasConcept C530470458 @default.
• W1966924789 hasConcept C71924100 @default.
• W1966924789 hasConcept C86803240 @default.
• W1966924789 hasConceptScore W1966924789C121608353 @default.
• W1966924789 hasConceptScore W1966924789C126322002 @default.
• W1966924789 hasConceptScore W1966924789C143998085 @default.
• W1966924789 hasConceptScore W1966924789C146357865 @default.
• W1966924789 hasConceptScore W1966924789C151730666 @default.
• W1966924789 hasConceptScore W1966924789C177713679 @default.
• W1966924789 hasConceptScore W1966924789C197934379 @default.
• W1966924789 hasConceptScore W1966924789C2775930923 @default.
• W1966924789 hasConceptScore W1966924789C2777063308 @default.
• W1966924789 hasConceptScore W1966924789C2777909004 @default.
• W1966924789 hasConceptScore W1966924789C2779134260 @default.
• W1966924789 hasConceptScore W1966924789C2781190966 @default.
• W1966924789 hasConceptScore W1966924789C29730261 @default.
• W1966924789 hasConceptScore W1966924789C526805850 @default.
• W1966924789 hasConceptScore W1966924789C530470458 @default.
• W1966924789 hasConceptScore W1966924789C71924100 @default.
• W1966924789 hasConceptScore W1966924789C86803240 @default.
• W1966924789 hasLocation W19669247891 @default.
• W1966924789 hasOpenAccess W1966924789 @default.
• W1966924789 hasPrimaryLocation W19669247891 @default.
• W1966924789 hasRelatedWork W1607913075 @default.
• W1966924789 hasRelatedWork W1973843163 @default.
• W1966924789 hasRelatedWork W1999128767 @default.
• W1966924789 hasRelatedWork W2077375498 @default.
• W1966924789 hasRelatedWork W2082857567 @default.
• W1966924789 hasRelatedWork W2083098315 @default.
• W1966924789 hasRelatedWork W2185958945 @default.
• W1966924789 hasRelatedWork W2405925945 @default.
• W1966924789 hasRelatedWork W2424618547 @default.
• W1966924789 hasRelatedWork W2590580834 @default.
• W1966924789 hasRelatedWork W2608581628 @default.
• W1966924789 hasRelatedWork W2765156323 @default.
• W1966924789 hasRelatedWork W2910205558 @default.
• W1966924789 hasRelatedWork W2944162800 @default.
• W1966924789 hasRelatedWork W2949907920 @default.
• W1966924789 hasRelatedWork W2964088882 @default.
• W1966924789 hasRelatedWork W3045062195 @default.
• W1966924789 hasRelatedWork W3125446430 @default.
• W1966924789 hasRelatedWork W3135295489 @default.
• W1966924789 hasRelatedWork W3213885198 @default.
• W1966924789 isParatext "false" @default.
• W1966924789 isRetracted "false" @default.
• W1966924789 magId "1966924789" @default.
• W1966924789 workType "article" @default.